Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Thermo Fisher Scientific Inc. is a leading provider of scientific instruments, reagents, and consumables, primarily serving the healthcare and life sciences sectors. The company operates globally, with a strong presence in North America and Europe, and is known for its advanced diagnostic solutions and laboratory equipment that drive innovation in research and clinical applications.
Thermo Fisher generates revenue through the sale of a diverse range of products and services, including laboratory equipment, reagents, and consumables. The company benefits from strong pricing power due to its reputation for quality and innovation, as well as its extensive distribution network and customer relationships.
Demand for diagnostic testing and laboratory services, particularly in response to public health needs
Innovation in life sciences research tools and technologies
Regulatory approvals for new products and services
Mergers and acquisitions that enhance product offerings or market share
Technological disruption from emerging competitors or alternative diagnostic methods
Regulatory changes that could impact product approvals and market access
Increased competition from both established players and startups in the life sciences sector
Pricing pressure from generic and lower-cost alternatives
Potential leverage from acquisitions that could strain financial resources
Currency fluctuations impacting international revenues
moderate - the company's performance is linked to healthcare spending and research funding, which can be influenced by economic cycles.
Thermo Fisher's financing costs may increase with rising interest rates, potentially impacting capital expenditures and acquisitions, but demand for healthcare products remains relatively inelastic.
minimal - the company has a strong balance sheet and is not heavily reliant on credit markets for operations.
growth - investors are drawn to the company's innovation potential and market leadership in diagnostics.
moderate - the stock has historically shown resilience, but can be affected by broader market trends and sector-specific news.
